In vitro activity of tigecycline and comparators against a European compilation of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial (TEST)

References

• DiNubile MJ, Lipsky BA. Complicated infections of skin and skin structures: when the infection is more than skin deep. J Antimicrob Chemother 2004;53(Suppl S2):ii37–50.
   PubMedGoogle Scholar
• Hecht DW. Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments. Clin Infect Dis 2004;39:92–7.
   PubMed Web of Science ®Google Scholar
• Salonen JH, Eerola E, Meurman O. Clinical significance and outcome of anaerobic bacteremia. Clin Infect Dis 1998;26:1413–7.
   PubMed Web of Science ®Google Scholar
• Koeth LM, Good CE, Appelbaum PC, Goldstein EJ, Rodloff AC, Claros M, . Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents. J Antimicrob Chemother 2004;53:1039–44.
   PubMed Web of Science ®Google Scholar
• Behra-Miellet J, Dubreuil L, Calvet L. Evaluation of the in vitro activity of ertapenem and nine other comparator agents against 337 anaerobic bacteria. Int J Antimicrob Agents 2006;28:25–35.
   PubMed Web of Science ®Google Scholar
• Wyeth Pharmaceuticals Inc. Tygacil prescribing information. Philadelphia, PA, USA; 2008. Available at: http://www.tygacil.com (accessed 20 January 2009).
   Google Scholar
• Edlund C, Nord CE. In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline. Clin Microbiol Infect 2000;6:158–63.
   Web of Science ®Google Scholar
• Nørskov-Lauritsen N, Marchandin H, Dowzicky MJ. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004–2007). Int J Antimicrob Agents 2009;34:121–30.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard—sixth ed. M11-A7. Wayne, PA: CLSI; 2008.
   Google Scholar
• European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints, March 12, 2008. Available at: http://www.srga.org/eucastwt/MICTAB/ (March 2009).
   Google Scholar
• Solomkin JS, Mazuski JE, Baron EJ, Sawyer RG, Nathens AB, DiPiro JT, . Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003;37:997–1005.
   PubMed Web of Science ®Google Scholar
• Nagy E, Szöke I, Gacs M, Csiszar K. Antibiotic susceptibility of Bacteroides fragilis group strains in Hungary. Anaerobe 1995;1:269–74.
   PubMed Web of Science ®Google Scholar
• Oteo J, Aracil B, Alóso I, Gómez-Garcés JL. High prevalence of resistance to clindamycin in Bacteroides fragilis group isolates. J Antimicrob Chemother 2000;45:691–3.
   PubMed Web of Science ®Google Scholar
• Hedberg M, Nord CE. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe. Clin Microbiol Infect 2003;9:475–88.
   PubMed Web of Science ®Google Scholar
• Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez H. Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents. Antimicrob Agents Chemother 2006;50:3507–13.
   PubMed Web of Science ®Google Scholar
• Liebetrau A, Rodloff AC, Behra-Miellet J, Dubreui L. In vitro activities of a new des-fluoro(6)quinolone, garenoxacin, against clinical anaerobic bacteria. Antimicrob Agents Chemother 2003;47:3667–71.
   PubMed Web of Science ®Google Scholar
• Liu CY, Huang YT, Liao CH, Yen LC, Lin HY, Hsueh PR. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob Agents Chemother 2008;52:3161–8.
   PubMed Web of Science ®Google Scholar
• Sóki J, Edwards R, Hedberg M, Fang H, Nagy E, Nord CE. Examination of cfiA-mediated carbapenem resistance in Bacteroides fragilis strains from a European antibiotic susceptibility survey. Int J Antimicrob Agents 2006;28:497–502.
   PubMed Web of Science ®Google Scholar
• Bradford PA, Weaver-Sands DT, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005;41:S315–32.
   PubMed Web of Science ®Google Scholar
• Goldstein EJ, Citron DM, Warren YA, Tyrrell KL, Merriam CV, Fernandez H. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother 2006;50:148–55.
   PubMed Web of Science ®Google Scholar
• Jacobus NV, McDermott LA, Ruthazer R, Snydman DR. In vitro activities of tigecycline against the Bacteroides fragilis group. Antimicrob Agents Chemother 2004;48:1034–6.
   PubMed Web of Science ®Google Scholar
• Betriu C, Culebras E, Gómez M, López F, Rodríguez-Avial I, Picazo JJ. Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain. Anti-microb Agents Chemother 2008;52:2686–90.
   PubMed Web of Science ®Google Scholar
• Betriu C, Culebras E, Gómez M, Rodríguez-Avial I, Picazo JJ. In vitro activity of tigecycline against Bacteroides species. J Antimicrob Chemother 2005;56:349–52.
   PubMed Web of Science ®Google Scholar
• King A, Downes J, Nord CE, Phillips I. Antimicrobial susceptibility of non-Bacteroides fragilis group anaerobic Gram-negative bacilli in Europe. Clin Microbiol Infect 1999;5:404–16.
   PubMedGoogle Scholar
• Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E, for the Tigecycline 301 and 306 Study Groups. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005;41:S354–67.
   Google Scholar
• Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E, for the Tigecycline 300 and 305 cSSSI Study Groups. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin–aztreonam. Clin Infect Dis 2005;41:S341–53.
   PubMed Web of Science ®Google Scholar
• Blairon L, De Gheldre Y, Delaere B, Sonet A, Bosly A, Glupczynski Y. A 62-month retrospective epidemiological survey of anaerobic bacteraemia in a university hospital. Clin Microbiol Infect 2006;12:527–32.
   PubMed Web of Science ®Google Scholar